Skip to main content

Table 1 Baseline Characteristics of Included NHANES Participants

From: Resistant hypertension and cardiovascular disease mortality in the US: results from the National Health and Nutrition Examination Survey (NHANES)

Characteristica

Non-aTRH

aTRH

Any Non-aTRH

Non-aTRH Subgroups

Any aTRH

aTRH Subgroups

< 3 medications

3 medications

Controlled

Uncontrolled

Definition: BP mm Hg and number of antihypertensives

< 140/90

AND

≤3

< 140/90

AND

< 3

< 140/90

AND

3

> 140/90

OR

≥3

< 140/90

AND

≥4

≥140/90

AND

≥3

Unweighted Population (N)

4835

3837

998

1522

432

1090

US Weighted Population (N in Millions)b

29.04

23.49

5.55

7.6

2.27

5.33

Age (years), mean (SE)

59.4 (0.3)

58.3 (0.3)

64 (0.3)

65.9 (0.5)

65.1 (0.6)

66.2 (0.8)

Age Categories

 Age < 45 years

510 (14.1)

457 (15.5)

53 (8)

69 (5.9)

14 (4.6)

55 (6.5)

 Age 45–65 years

2055 (48.8)

1709 (51)

346 (39.3)

456 (35.5)

138 (38.7)

318 (34.2)

 Age ≥ 65 years

2270 (37.1)

1671 (33.4)

599 (52.8)

997 (58.5)

280 (56.7)

717 (59.3)

Sex

 Female

2607 (55.1)

2094 (55.3)

513 (54.2)

819 (57.4)

209 (52.5)

610 (59.5)

 Male

2228 (44.9)

1743 (44.7)

485 (45.8)

703 (42.6)

223 (47.5)

480 (40.5)

Race/Ethnicity

 Non-Hispanic White

2645 (78.3)

2073 (78.5)

572 (77.3)

787 (73.4)

224 (74.4)

563 (73)

 Non-Hispanic Black

1221 (12.3)

959 (12)

262 (13.8)

491 (18.3)

147 (18.1)

344 (18.4)

 Mexican American

823 (5.4)

685 (5.4)

138 (5.7)

210 (5)

51 (4.7)

159 (5.1)

 Other

146 (4)

120 (4.2)

26 (3.3)

34 (3.3)

10 (2.8)

24 (3.5)

Ever or Current Smoker

2643 (55.1)

2077 (55.3)

566 (53.8)

838 (53.1)

257 (58.4)

581 (50.8)

Diabetes

1459 (24.5)

1090 (22.7)

369 (32.4)

661 (39.5)

210 (44.1)

451 (37.5)

Prior CVD

1101 (18.9)

750 (15.9)

351 (31.4)

636 (40.1)

213 (48.5)

423 (36.4)

Body mass index (kg/m2), mean (SE)

30.8 (0.1)

30.6 (0.1)

31.8 (0.3)

32.1 (0.3)

33.2 (0.5)

31.7 (0.3)

Systolic blood pressure (mmHg), mean (SE)

122.2 (0.2)

122.3 (0.2)

121.7 (0.4)

144.7 (0.7)

119.7 (0.7)

155.4 (0.6)

Diastolic blood pressure (mmHg), mean (SE)

69.6 (0.3)

70.3 (0.3)

66.6 (0.5)

71.1 (0.5)

63.6 (0.9)

74.3 (0.6)

# of anti-hypertensives, mean (SE)

1.77 (0.01)

1.48 (0.01)

3 (0)

3.67 (0.03)

4.26 (0.03)

3.41 (0.03)

Diuretics

2333 (46.3)

1512 (37.5)

821 (83.5)

1310 (86.8)

404 (93.5)

906 (83.9)

ACE-i or ARB

2563 (63.4)

1862 (59.8)

701 (77.9)

1115 (83.2)

370 (89.3)

745 (80.2)

Calcium channel blockers

1348 (24.5)

890 (20.2)

458 (43)

892 (56.6)

283 (65.1)

609 (53)

Beta blockers

1555 (34.6)

997 (29)

558 (58.1)

991 (66.6)

326 (77.2)

665 (62)

Other

481 (8)

281 (5.7)

200 (17.5)

624 (38.1)

211 (45.9)

413 (34.7)

Total Cholesterol (mmol/L), mean (SE)

5.2 (0.02)

5.2 (0.03)

5.1 (0.05)

5.2 (0.05)

4.8 (0.08)

5.3 (0.05)

eGFR (mL/min/1.73 m2), median (IQR)

82 (66, 96)

84 (69, 97)

71 (58, 87)

68 (51, 85)

67 (52, 86)

68 (51, 85)

CRP (mg/dL), mean (SE)

0.56 (0.02)

0.54 (0.02)

0.65 (0.04)

0.68 (0.03)

0.67 (0.05)

0.68 (0.04)

ACR (mg/g), median (IQR)

7 (5, 15)

7 (5, 13)

9 (5, 22)

14 (6, 49)

10 (6, 26)

17 (7, 67)

  1. Data are presented as N (%) and mean (SE), unless otherwise indicated
  2. Abbreviations: USRDS United States Renal Data System, SE Standard Error, CVD Cardiovascular Disease, eGFR estimated Glomerular Filtration Rate, IQR Interquartile Range, CRP C-reactive Protein, ACR Albumin-Creatinine Ratio, aTRH apparent treatment resistant hypertension, ACE-i angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers, SE standard error
  3. a Unweighted refers to the actual number (%) of the NHANES participants from the final cohort
  4. b Weighted refers to the projected numbers in the US populations and accounts for NHANES design and sampling weights